Plasma Paraoxonase-1, Oxidized Low-Density Lipoprotein and Lipid Peroxidation Levels in Gout Patients

Cell Biochemistry and Biophysics

Volumn 61, Issue 2, 2011, Pages 461-466

  Jiang, Xing Liang ^a   Li, Min ^a   Zhou, Jing Guo ^a   Yang, Qi Bin ^a   Du, Li Jun ^a   Du, Juan ^a  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

Author keywords

Gout; Lipid peroxidation; Oxidized low density lipoprotein; Paraoxonase 1

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZING AGENT; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; BLOOD; ENZYMOLOGY; GOUT; HUMAN; LIPID PEROXIDATION; MALE; METABOLISM; MIDDLE AGED;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; GOUT; HUMANS; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDANTS; SUPEROXIDE DISMUTASE;

EID: 80955143028     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9221-5     Document Type: Article

References (35)

1. Choi, H. K., Mount, D. B., & Reginato, A. M. (2005). Pathogenesis of gout. Annals of Internal Medicine, 143, 499-516.
2. Krishnan, E., Svendsen, K., Neaton, J. D., Grandits, G., & Kuller, L. H. (2008). Long-term cardiovascular mortality among middle-aged men with gout. Archives of Internal Medicine, 168, 1104-1110.
3. Takahashi, S., Yamamoto, T., Moriwaki, Y., Tsutsumi, Z., & Higashino, K. (1995). Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Annals of the Rheumatic Diseases, 54, 90-93.
4. Mak, A., Ho, R. C. M., Tan, J. Y. S., et al. (2009). Atherogenic serum lipid profile is an independent predictor for gouty flares in patients with gouty arthropathy. Rheumatology, 48, 262-265.
5. Cheng, T. T., Lai, H. M., Chang, H. W., & Luo, S. F. (2005). Elevated serum homocysteine levels for gouty patients. Clinical Rheumatology, 24, 103-106.
6. Krishnan, E. (2010). Inflammation, oxidative stress and lipids: The risk triad for atherosclerosis in gout. Rheumatology, 3, 1-10.
7. Madamanchi, N. R., Vendrov, A., & Runge, M. S. (2005). Oxidative stress and vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 25, 29-38.
8. Hahn, M., & Subbiah, M. T. (1994). Significant association of lipid peroxidation products with high density lipoproteins. Biochemistry and Molecular Biology International, 33, 699-704.
9. Steinberg, D. (1997). Low density lipoprotein oxidation and its pathobiological significance. The Journal of Biological Chemistry, 272, 20963-20966.
10. Navab, M., Anantharamaiah, G. M., Reddy, S. T., van Lenten, B. J., Ansell, B. J., & Fogelman, A. M. (2006). Mechanisms of disease: Proatherogenic HDL-an evolving field. Nature Clinical Practice Endocrinology & Metabolism, 2, 504-511.
11. Mackness, M., Durrington, P., & Mackness, B. (2004). Paraoxonase-1 activity, concentration and genotype in cardiovascular disease. Current Opinion in Lipidology, 15, 399-404.
12. Mackness, B., Davies, G. K., Turkie, W., et al. (2001). Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 1451-1457.
13. Esterbauer, H., Schaur, R. J., & Zollner, H. (1991). Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radical Biology and Medicine, 11, 81-128.
14. Beckman, J. S., & Koppenol, W. H. (1996). Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and the ugly. American Journal of Physiology, 271, C3424-3437.
15. Wallace, S. L., Robinson, H., Masi, A. T., Decker, J. L., McCarty, D. J., & Yu, T. F. (1997). Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism, 20, 895-900.
16. Ferre, N., Camps, J., Prats, E., et al. (2008). Serum paraoxonase activity: A new additional test for the improved evaluation of chronic liver damage. Clinical Chemistry, 48, 261-268.
17. Aviram, M., Rosenblat, M., Billecke, S., et al. (1999). Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biology and Medicine, 26, 892-904.
18. Nakamura, K., Endo, H., & Kashiwazaki, S. (1987). Serum oxidation activities and rheumatoid arthritis. International Journal of Tissue Reactions, 9, 307-316.
19. Mackness, B., Hunt, R., Durrington, P. N., & Mackness, M. I. (1997). Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 17, 1233-1238.
20. Feingold, K. R., Memon, R. A., Moser, A. H., & Grunfeld, C. (1998). Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis, 139, 307-315.
21. Mackness, M. I., Arrol, S., & Durrington, P. N. (1991). Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Letters, 286, 152-154.
22. Inokuchi, T., Moriwaki, Y., Tsutsui, H., et al. (2006). Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18. Cytokine, 33, 21-27.
23. Kumon, Y., Nakauchi, Y., Suehiro, T., et al. (2002). Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid, 9, 160-164.
24. James, R. W., & Deakin, S. P. (2004). The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radical Biology and Medicine, 37, 1986-1994.
25. Deakin, S., Leviev, I., Gomaraschi, M., Calabresi, L., Franceschini, G., & James, R. W. (2002). Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. The Journal of Biological Chemistry, 277, 4301-4308.
26. Rashid, S., Uffelman, K. D., & Lewis, G. F. (2002). The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. Journal of Diabetes Complications, 16, 24-28.
27. Roubenoff, R., Klag, M. J., Mead, L. A., Liang, K. Y., Seidler, A. J., & Hochberg, M. C. (1991). Incidence and risk factors for gout in white men. The Journal of the American Medical Association, 266, 3004-3007.
28. Patterson, R. A., Horsley, E. T., & Leake, D. S. (2003). Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: Important role of uric acid. Journal of Lipid Research, 44, 512-521.
29. Abuja, P. M. (1999). Ascorbate prevents prooxidant effects of urate in oxidation of human low density lipoprotein. FEBS Letters, 446, 305-308.
30. Muraoka, S., & Miura, T. (2003). Inhibition by uric acid of free radicals that damage biological molecules. Pharmacology and Toxicology, 93, 284-289.
31. Maples, K. R., & Mason, R. P. (1988). Free radical metabolite of uric acid. The Journal of Biological Chemistry, 263, 1709-1712.
32. Santos, C. X., Anjos, E. I., & Augusto, O. (1999). Uric acid oxidation by peroxynitrite: Multiple reactions, free radical formation, and amplification of lipid oxidation. Archives of Biochemistry and Biophysics, 372, 285-294.
33. Sautin, Y. Y., Nakagawa, T., Zharikov, S., & Johnson, R. J. (2007). Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase mediated oxidative/nitrosative stress. American Journal of Physiology, 293, C584-C596.
34. Bartesaghi, S., Ferrer-Sueta, G., Peluffo, G., et al. (2007). Protein tyrosine nitration in hydrophilic and hydrophobic environments. Amino Acids, 32, 501-515.
35. Bagnati, M., Perugini, C., Cau, C., Bordone, R., Albano, E., & Bellomo, G. (1999). When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: A study using uric acid. Biochemical Journal, 340, 143-152.